Should I buy Piramal Pharma stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Piramal Pharma for over three years. Every month, lakhs of users in India trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment recommendations. In accordance with our ethical charter, we have never been, and will never be, compensated by Piramal Pharma.

What is Piramal Pharma?

What is the Piramal Pharma stock price?

The price of Piramal Pharma stock is rising this week. Trading at ₹203.66, Piramal Pharma gained 0.61% in the last 24 hours and is up 0.41% over the week. The company holds a market capitalization of ₹27,071 crores, with an average 3-month volume of 4.24 million shares. Its P/E Ratio is 295.16, with a modest dividend yield of 0.07% and a beta of 0.84, indicating lower volatility than the market average. Piramal Pharma’s recent strong trading and positive outlook suggest attractive investment potential, especially as the sector expands.

Our Full Analysis of the Piramal Pharma Stock

We have carefully reviewed Piramal Pharma’s latest financial results and the stock’s dynamic performance over the past three years. Our analysis synthesizes multiple data streams—financial metrics, technical signals, market behavior, and competitive landscape—processed with our proprietary evaluation model. So, why might Piramal Pharma stock once again become a strategic entry point into the healthcare and pharmaceutical sector in 2025?

Recent performance and market context

Piramal Pharma has staged a remarkable rebound in the last year, with its share price currently at ₹203.66—climbing 0.61% over the past day and registering a week-on-week gain of 0.41%. Despite a 20.09% decline over the past six months, the stock delivered an impressive 29.42% gain year-on-year, underlining its ability to recover and ride sectoral trends in Indian pharmaceuticals. The company’s current market capitalization stands at ₹27,071 crores, reflecting its strong presence among India’s healthcare leaders. Recent positive catalysts include a substantial 52% year-on-year jump in net profit for Q4 FY25, settlement of significant legal disputes, and the announcement of a final dividend—each instilling renewed confidence among market watchers. Against a backdrop of India’s rapidly growing pharmaceutical exports and widespread adoption of contract development and manufacturing (CDMO) by global and domestic players, Piramal Pharma finds itself strategically poised within a robustly expanding sector.

Technical analysis

On the technical front, Piramal Pharma is demonstrating constructive signals that support a bullish investing stance. The current 14-day RSI sits at 53.03, indicating balance—neither overbought nor oversold—and leaving room for upward movement should buying pressure intensify. The MACD has just shifted positive at 0.08, supporting a recent upward price inflection signaled by a bullish 5-day EMA crossover. The stock price is presently positioned above the 20-day moving average (₹200.76) and is closing in on the 50-day average (₹205.36), having shown resilience close to key support zones at ₹199.03 and ₹194.41. Immediate resistance awaits at ₹206.50 and ₹209.35, which, if surpassed, could trigger new episodes of medium-term momentum. Piramal Pharma’s overall technical structure, with prices mostly trending above short-term averages and positive momentum gathering, points to a favorable environment for upward price action as investor conviction rebuilds.

Fundamental analysis

Piramal Pharma boasts a combination of robust fundamentals and strategic positioning that makes the stock increasingly compelling. The latest Q4 FY25 results reveal quarterly revenue of ₹2,754 crores—an annual increase of 7.9%—accompanied by EBITDA of ₹561 crores (+5.9% YoY) and net profit surging to ₹153.50 crores (+52% YoY). Such outperformance versus consensus estimates demonstrates the company’s ongoing margin recovery and effective execution. Annualized, these figures suggest an accelerating upward trajectory, with management guiding for a healthy 12% revenue growth in FY25, underpinned by a strong order book and healthy demand from regulated markets.

While the P/E ratio is elevated at 295.16, it reflects forward-looking investor confidence as Piramal Pharma consolidates its position as the 3rd largest CDMO in India and 13th globally, with an expanding client base now exceeding 500 regulated-market customers. The brand’s strength in complex generics and hospital products, combined with ongoing innovation around integrated CDMO solutions, dramatically enhances its competitive moat. The business enjoys operational leverage owing to a diverse network of 15 world-class sites and an increasing share of high-margin, integrated projects (40% of new orders in FY24), all contributing to margin expansion.

Structural strengths are reinforced by the company’s strategic diversification, proven research and development capabilities, and an exceptional track record for regulatory compliance—key attraction points as India’s healthcare reforms accelerate and investor flows increasingly favor innovative, globally-oriented pharmaceutical platforms.

Volume and liquidity

Piramal Pharma’s average trading volume of 4.24 million shares over the past 20 days ensures ample liquidity and smooth price discovery, enabling institutional and retail investors alike to transact without major slippage. The stock’s robust float structure, with significant participation from foreign institutional investors (FII: 31.49%), domestic institutional investors (DII: 14.78%), and a committed promoter base (34.95%), supports a stable shareholder ecosystem, minimizing the risk of excessive volatility while retaining scope for dynamic valuation growth. This steady turnover, coupled with a growing institutional footprint, is a hallmark of confidence and liquidity—an advantage for both long-term investors and tactical traders.

Catalysts and positive outlook

• Continued expansion in the global CDMO arena, where Piramal Pharma’s growing leadership is aligned with rising pharmaceutical outsourcing demand, both domestically and internationally.
• Strategic growth in integrated project solutions, a segment that delivers higher margins and stickier client relationships, now accounting for 40% of new orders.
• Successful resolution of pending legal disputes and the closure of the Astral SteriTech insolvency, which have de-risked the near-term operational landscape and freed up capital for reinvestment and dividends.
• Regular recognition for ESG and regulatory excellence, including consistent compliance in highly regulated export markets, ensures access to premium markets and builds long-term value.
• The company’s innovation pipeline, with a focus on complex generic drugs and high-value specialty formulations, positions it to capitalize on rapidly shifting healthcare demands and new product launches.
• Final dividend declarations underscore commitment to shareholder returns and financial discipline, reinforcing long-term confidence.

Investment strategies

For those seeking short-term entry, the current technical configuration—marked by support near ₹199 and a clear upward price structure—offers an attractive risk-reward set-up, particularly as bullish technical signals converge with earnings momentum and recent dividend announcements. Medium-term investors may find opportunity in the upcoming cycle of order wins and product launches, with potential for price appreciation as the company’s growing role in the CDMO sector receives further recognition from the market. Long-term holders, meanwhile, are well positioned to benefit from the company’s powerful combination of operational scale, global market reach, and consistent innovation, making Piramal Pharma a strong anchor for healthcare-focused portfolios seeking not only capital gains but robust business continuity.

Ideal entry points may be found following consolidation phases near support levels, or ahead of anticipated catalysts such as quarterly earnings or new contract announcements. Employing a phased accumulation strategy or utilizing trailing stops can further enhance portfolio efficiency and manage market risk.

Is it the right time to buy Piramal Pharma?

Piramal Pharma unites strong recent performance, accelerating earnings, sectoral leadership, and a wave of innovation—qualities that decisively set it apart in a crowded sector. The company’s global footprint in regulated CDMO markets, ambitious expansion plans, and operational excellence all reinforce the case for renewed interest. While the premium P/E valuation suggests careful position sizing, the overall risk-reward profile is enhanced by robust liquidity, a deep institutional base, and favorable market conditions. For investors seeking resilient growth, access to India’s vibrant healthcare sector, and exposure to a premier name in pharmaceutical innovation, Piramal Pharma seems to represent an excellent opportunity as the sector enters a new phase of expansion. With multiple catalysts on the horizon, ongoing order flow strength, and financial discipline, the stock may be entering a new bullish phase. For both tactical and long-term investors, Piramal Pharma holds the potential to be a cornerstone in a modern growth portfolio aligned with India’s health and innovation trajectory.

How to buy Piramal Pharma stock?

Buying Piramal Pharma stock online is both straightforward and secure when using a SEBI-regulated broker in India. Investors can choose between two main options: directly purchasing shares for full ownership (spot buying) or trading Contracts for Difference (CFDs) for leveraged exposure without holding the actual shares. Each method is accessible in just a few clicks and accommodates different investor preferences. You’ll find a comparison of top brokers further down this page to help you select the right platform for your goals.

Spot buying

A cash or spot purchase of Piramal Pharma shares means you own the shares directly, allowing you to benefit from price appreciation and dividend payouts. Indian brokers usually charge a fixed commission for each trade, typically ₹15–₹30 per order.

Piramal Pharma Share: Gain Scenario Example

If the Piramal Pharma share price is ₹203.66, you can buy around 48 shares with a $1,000 stake (approx. ₹83,000), including a brokerage fee of about $5 (₹415).

Gain scenario: If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading on Piramal Pharma allows you to speculate on the share price—up or down—without actually owning the stock. Brokers apply a spread (difference between buy/sell price) and charge overnight financing fees if positions are held for multiple days. CFDs are popular for providing leverage, magnifying both potential returns and risks.

CFD Trading Example: Gain Scenario

You open a CFD position on Piramal Pharma shares, with 5x leverage and a $1,000 stake. This gives you a market exposure of $5,000.

✔️ Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before buying Piramal Pharma shares, take the time to compare brokers’ fees, trading conditions, and available features for both spot buying and CFDs. The right choice depends on your objectives, investment horizon, and risk appetite. A detailed broker comparator is provided further down this page to support your decision-making with confidence.

Our 7 tips for buying Piramal Pharma stock

The latest news about Piramal Pharma

Piramal Pharma delivered a 0.61% share price gain over the past 24 hours on NSE. The stock closed at ₹203.66, reflecting cautious optimism among domestic investors, supported by stable demand for healthcare and pharmaceutical services in India, and a generally positive outlook on regulated markets.

The latest quarterly report showed a net profit jump of 52% year-on-year for Q4 FY25. Net income reached ₹153.50 crores, reflecting operational efficiency and strong demand for the company’s CDMO (Contract Development and Manufacturing Organization) services. Results exceeded market expectations and reinforce Piramal Pharma’s leadership among Indian pharmaceutical exporters.

The board declared a final FY25 dividend of ₹0.14 per share, confirming consistent shareholder returns. While modest, this dividend underscores management’s commitment to sharing profits and maintaining investor confidence—a particularly relevant point for Indian retail and institutional shareholders.

Piramal Pharma’s recent dispute settlement brought in an additional USD 2.42 million. The digital payment related to regulatory litigation resolution has bolstered the company’s short-term liquidity and provided further stability for ongoing expansion efforts within the Indian market.

Technical signals point to a favorable momentum, including a bullish 5-day EMA on 4th July 2025. Combined with a neutral RSI (53.03) and buy signals from the MACD, these trends suggest ongoing accumulation by investors, capturing increasing interest from both domestic and global funds focused on India’s growth sectors.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.